Enhanced Fertility test kit and digital platform certification for new market entry

世界卫生组织将不孕症定义为无保护性交6个月（对于< 35岁的女性）或12个月（对于>35岁的女性）后无法怀孕。它影响着全世界1/6的人。他们平均需要7年才能生一个孩子：3.2年获得诊断，然后是1.6年获得专家，再加上2.2年的生育治疗。增强生育已经解决了“3.2年诊断”和“1.6年获得专家”与家庭诊断测试试剂盒，一个有效的在线评估，一个患者门户网站，提供AI/ML驱动的建议和更快的专家转诊。英国的患者可以通过Enhanced Fertility应用程序获得这些服务。在赢得InnovateUK女性创新奖后，Enhanced Fertility开始建立一个数字平台，以解决“2.2年的生育治疗”问题。该医生门户网站将于2022年9月推出，允许专业临床医生在治疗前为英国患者请求测试，可视化患者的健康数据，远程评估这些患者并获得数据驱动决策的见解（精确医学）。目前的建议是一个为期6个月的项目，以认证增强生育测试套件和本地化门户软件，作为一个新的地理市场进入欧盟，产生新的收入来源。患者将受益于更快地获得诊断，临床医生将能够远程评估他们的患者，无论是在英国还是欧盟，并使用数据驱动的见解来做出个性化生育护理的决策。

The World Health Organisation defines infertility as the inability to conceive after 6 months (for women < 35) or 12 months (for women \>35) of unprotected intercourse. It affects 1/6 people worldwide.It takes them on average 7 years to have a baby: 3.2 years to get a diagnosis, followed by 1.6 years to access a specialist, and a further 2.2 years of fertility treatment.Enhanced Fertility is already addressing the '3.2 years to diagnosis' and '1.6 years to access a specialist' with at-home diagnostic test kits, a validated online assessment, a Patient Portal with AI/ML-driven recommendations and faster referrals to specialists. Patients in the UK can access these services through the Enhanced Fertility App.After winning the InnovateUK Women in Innovation Award, Enhanced Fertility has started building a digital platform to address the '2.2 years of fertility treatment'. This Doctor's Portal will be available by September 2022 and will allow specialist clinicians to request tests for their UK patients ahead of treatment, visualise patients' health data, assess these patients remotely and receive insights for data-driven decision-making (precision medicine).The present proposal is a 6-month project to certify the Enhanced Fertility test kit and to localise the portal software, affording EU entry as a new geographic market, generating a new revenue stream. Patients will benefit from faster access to diagnostics and clinicians will be able to assess their patients remotely, both in the UK and EU, and use data-driven insights to make decisions that personalise fertility care.